Clinical Trial Update: Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating amifampridine phosphate in spinal muscular atrophy type 3 patients has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy Type

Drugs mentioned

• Amifampridine phosphate (amifampridine phosphate)

Snippet

Sponsor: Catalyst Pharmaceuticals, Inc. | Conditions: Muscular Atrophy, Spinal | Phase 2 | Status: COMPLETED | Results posted: 2021-06-01